Myelofibrosis is a bone marrow disorder that causes the body's synthesis of blood cells to be disrupted. In the bone marrow, fibrous or scar tissue develops, causing scarring and inadequate blood cell generation. Myelofibrosis is an uncommon form of persistent leukemia that affects the formation of blood. Severe anemia, fatigue, weakness, and an enlarged spleen are all symptoms of myelofibrosis. Individuals above the age of 50 are more likely to get the illness. Primary myelofibrosis and secondary myelofibrosis are the two kinds of myelofibrosis. The therapy options are limited, but in 2011, the United States Food and Medication Administration (FDA) authorized Jakafi (Ruxolitinib), a Novartis drug that is the sole approved product for the treatment of myelofibrosis and serves as a key line of defense against the illness.
The rising frequency of myelofibrosis in developing nations is driving demand for various myelofibrosis treatment alternatives. Because of substantial expenditures in research and development, acceptable reimbursement conditions, and a huge pool of patients with myelofibrosis, the market is projected to increase. Other factors contributing to market expansion include lifestyle advancements, unmet medical requirements of patients, rising rates of genetic diseases, and an expanding smoking population. With medical advancements focusing on patients suffering from myelofibrosis, the market is expected to grow significantly. For example, Gilead Sciences developed CYT387 or Momelotinib to treat primary myelofibrosis, and Incyte Corporation innovated the current medication, ruxolitinib, to establish a replacement dosage approach in patients with myelofibrosis.
However, the worldwide myelofibrosis therapy market is being held back by a lack of knowledge of innovative treatments and the high costs associated with treatment. With the growing frequency of myelofibrosis and attractive reimbursement scenarios, North America is expected to lead the market.